证券代码：600196 证券简称：复星医药 公告编号：2025-162 上海复星医药（集团）股份有限公司 2025年第一次临时股东会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议有无否决议案：无 一、 会议召开和出席情况 （一）股东会召开的时间：2025 年 10 月 23 日 （二）股东会召开的地点：上海市虹许路 358 号上海天禧嘉福璞缇客酒店 （三）出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 1,640 | | --- | --- | | 其中：境内上市内资股（A 股）股东人数 | 1,639 | | 境外上市外资股（H 股）股东人数 | 1 | | 2、出席会议的股东所持有表决权的股份总数（股） | 1,100,625,377 | | 其中：境内上市内资股（A 股）股东持有表决权股份总数（股） | 977,104,664 | | 境外上市外资股（H 股）股东持有表决权股份总数（股） | 123,520,713 | | 注的 ...

Core Viewpoint - Southbound funds increased their holdings in Fosun Pharma (02196.HK) by 316,500 shares on October 22, 2025, despite experiencing net reductions in holdings on several days in the preceding weeks [1][2]. Group 1: Shareholding Changes - Over the last five trading days, there were two days of net reductions in holdings, totaling a net decrease of 296,000 shares [1]. - In the last twenty trading days, there were twelve days of net reductions, resulting in a cumulative net decrease of 16.5155 million shares [1]. - As of now, southbound funds hold 306 million shares of Fosun Pharma, accounting for 55.51% of the company's total issued ordinary shares [1]. Group 2: Company Overview - Fosun Pharma is primarily engaged in the research, manufacturing, and sales of pharmaceutical products, operating through five divisions [2]. - The pharmaceutical division focuses on innovative drugs, mature pharmaceutical products, and vaccines [2]. - The medical devices and diagnostics division is involved in the manufacturing and sales of molecular diagnostics, immunodiagnostics, and microbiological diagnostic devices [2]. - The healthcare services division operates an integrated online and offline medical service platform [2]. - The pharmaceutical distribution and retail division is responsible for the wholesale and retail of pharmaceutical products [2]. - The company's products are mainly used in the treatment of oncology, immunology, and central nervous system disorders [2].

10月22日，据复星医药消息，近日，复星医药与赫尔森集团共同宣布，双方达成了止吐药物磷奈匹坦帕 洛诺司琼注射用浓溶液本地化生产战略合作。 ...

Economic Overview - Shanghai's GDP for the first three quarters reached 40,721.17 billion yuan, with a year-on-year growth of 5.5% [1] - The industrial production maintained a growth trend, with the industrial added value increasing by 5.2% year-on-year [2] Industrial Performance - The total industrial output value for large-scale industries in Shanghai grew by 5.7% year-on-year, with an acceleration of 0.1 percentage points compared to the first half of the year [2] - Key sectors such as railway, shipbuilding, aerospace, and other transportation equipment manufacturing saw a significant increase of 15.9% [2] - Electrical machinery and equipment manufacturing grew by 14.3%, while computer, communication, and other electronic equipment manufacturing increased by 12.1% [2] Investment Trends - Industrial investment in Shanghai rose by 20.3%, outpacing the overall fixed asset investment growth rate of 14.3 percentage points [2] - The resilience and internal driving force of industrial growth have been enhanced, indicating a positive investment outlook for future production [2] Emerging Industries - The three leading industries in Shanghai experienced an 8.5% increase in output value, surpassing the overall industrial growth by 2.8 percentage points [3] - The artificial intelligence manufacturing sector grew by 12.8%, and integrated circuit manufacturing increased by 11.3% [3] - High-tech manufacturing output value rose by 10.3%, with aerospace and communication equipment manufacturing growing by 20.6% and 13.4%, respectively [3] Strategic Initiatives - Shanghai is focusing on enhancing its artificial intelligence industry by aiming for a tripling of innovative enterprises, industry scale, and talent [4] - The city has established 12 national-level intelligent factories and 254 advanced intelligent factories, leading the nation in smart manufacturing [4] - In the biopharmaceutical sector, Shanghai's industry scale is expected to exceed 1 trillion yuan this year, with significant advancements in innovative drug approvals [5] Future Industry Development - Shanghai aims to cultivate a number of future industry clusters and lead in disruptive technologies by 2027 [5] - The city plans to nurture around 20 leading enterprises in future industries and establish itself as a globally influential hub by 2030 [5]

Meeting Overview - The company will hold its first extraordinary general meeting of 2025 on October 23, 2025, at 13:30 in Shanghai [1][4] - The meeting will be conducted using a combination of on-site and online voting methods [4][10] Voting Procedures - A-share shareholders can vote through the Shanghai Stock Exchange's online voting system, with specific time slots for voting on the meeting day [1][7] - Shareholders must complete identity verification to vote on the internet for the first time [7] - Votes exceeding the number of shares held will be considered invalid [8] Attendance and Registration - A-share shareholders must register in person with required identification and documentation on the day of the meeting [15] - H-share shareholders have separate registration procedures detailed on the Hong Kong Stock Exchange website [11][16] Agenda Items - The meeting will review several resolutions, including special resolutions and those requiring abstention from related shareholders [3][5] - Detailed agenda items were published on September 30, 2025 [3][4]

Core Insights - The attitude of foreign capital towards Chinese medical assets has dramatically reversed within a year, shifting from a neutral to a positive outlook on the biotechnology sector in China [1][3][7] Group 1: Market Sentiment Shift - Morgan Stanley's report titled "China Biotech: Innovation Dawn" indicates that China's biotechnology sector is now viewed as a critical part of the global new drug supply chain, with projected pharmaceutical revenues reaching $34 billion by 2030 and $220 billion by 2040 [1][3] - The number of foreign institutions conducting research on Chinese biotech companies has surged, with notable firms like State Street Bank and BlackRock showing increased interest [1][2] - The collective buying actions of foreign investors, such as JPMorgan and Citigroup, reflect a significant shift in sentiment towards Chinese innovative drug companies [2][5] Group 2: Investment Dynamics - The efficiency of converting research interest into actual holdings is evident, as seen in the stock price surge of WuXi AppTec, which rose by 6.52% due to increased foreign investment [2] - Major foreign investors have increased their holdings in key Chinese biotech firms, indicating a trend of strategic accumulation among top foreign capital [5][6] - The report highlights that foreign capital is now viewing specific sectors in China as essential assets in the global technology race, with over 90% of U.S. investors expressing plans to increase exposure to Chinese stocks, particularly in biotechnology [6][7] Group 3: Industry Evolution - The narrative surrounding China's pharmaceutical industry has shifted from being cost-driven to innovation-driven, acknowledging the significant advancements in the sector [3][4] - Morgan Stanley and Goldman Sachs both emphasize the growing recognition of China's innovative capabilities in biotechnology, with expectations that several leading biotech firms will reach breakeven by 2025-2026 [4][8] - The report outlines that the Chinese biotech sector is becoming a key player in filling the revenue gaps created by patent expirations in multinational corporations (MNCs), with an estimated $115 billion revenue loss due to patent cliffs by 2035 [8][10] Group 4: Future Projections - By 2040, China's share of FDA-approved drugs is expected to rise from 5% to 35%, with a projected global sales figure exceeding $1.22 trillion even in the most pessimistic scenarios [25][27] - The report anticipates that the collaboration between MNCs and Chinese biotech firms will intensify, driven by the need to address revenue shortfalls from patent expirations [10][14] - The overall improvement in clinical trial data integrity and the increasing number of new molecular entities launched in China are contributing to a more favorable investment landscape [20][22]

Meeting Overview - The company will hold its first extraordinary general meeting of 2025 on October 23, 2025, at 13:30 in Shanghai [1][4] - The meeting will utilize both on-site and online voting methods [4] Voting Procedures - Online voting will be available from 9:15 to 15:00 on the day of the meeting, with specific time slots for trading system voting [1][4] - A-share shareholders can vote through the Shanghai Stock Exchange's online voting system [6][9] Agenda Items - The meeting will discuss several special resolution proposals, including items 1 to 5, and separate voting for minority investors on items 1 to 8 [5][6] - Related proposals will require certain shareholders to abstain from voting [6] Attendance Requirements - A-share shareholders must register for the meeting with appropriate identification and documentation [11][12] - H-share shareholders have specific registration procedures detailed on the Hong Kong Stock Exchange website [10][13] Additional Information - Shareholders are responsible for their own travel and accommodation expenses [14] - Contact information for the company's board secretary office is provided for further inquiries [15]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損 失承擔任何責任。 上 海 復 星 醫 藥（ 集 團 ）股 份 有 限 公 司 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* （於中華人民共和國註冊成立的股份有限公司） （股份代號：02196） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條而作出。 茲載列上海復星醫藥（集團）股份有限公司（「本公司」）在上海證券交易所網站刊登的《關於 召開2025 年第一次臨時股東會的提示性公告》，僅供參閱。 承董事會命 上海復星醫藥（集團）股份有限公司 董事長 陳玉卿 中國，上海 2025 年1 0 月2 1 日 於本公告日期，本公司之執行董事為陳玉卿先生、關曉暉女士、文德鏞先生及王可心先生；本公司之非執行 董事為陳啟宇先生及潘東輝先生；本公司之獨立非執行董事為余梓山先生、王全弟先生、Chen Penghui先生 及楊玉成先生；以及本公司之職工董事為嚴佳女 ...

证券代码：600196 证券简称：复星医药 公告编号：2025-161 上海复星医药（集团）股份有限公司 关于召开 2025 年第一次临时股东会的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 上海复星医药（集团）股份有限公司（以下简称"本公司"）兹定于2025年10月 23日下午13:30在上海市虹许路358号上海天禧嘉福璞缇客酒店召开2025年第一次临 时股东会（以下简称"本次会议"）。现将有关参会事宜再次提示如下： 一、本次会议基本情况 （一）股东会类型和届次：2025 年第一次临时股东会 （二）股东会召集人：董事会 （三）A 股股东投票方式：采用现场投票和网络投票相结合的方式 （四）现场会议召开的日期、时间和地点 召开的日期时间：2025 年 10 月 23 日 13 点 30 分 召开地点：上海市虹许路 358 号上海天禧嘉福璞缇客酒店 涉及融资融券、转融通业务、约定购回业务相关账户以及沪股通投资者的投票， 应按照《上海证券交易所上市公司自律监管指引第 1 号—规范运作》等有关规定执行。 （七）涉及公开征 ...

Core Viewpoint - The market experienced a correction last week, but certain stocks within the brand index showed resilience, indicating potential investment opportunities in sectors like electronics, new energy, new consumption, and real estate as uncertainties ease [1][4]. Market Performance - The market indices saw declines: Shanghai Composite Index down 1.47%, Shenzhen Component down 4.99%, ChiNext down 5.71%, and CSI 300 down 2.22%. The brand index fell 3.58% to 1956.62 points [2]. - Notable gainers in the brand index included Shanghai Jahwa up 9.42%, Changbai Mountain up 7.19%, and Darentang up 5.34%. Other stocks like Luzhou Laojiao and Yiling Pharmaceutical also saw gains exceeding 4% [2]. Stock Performance Since H2 - Since the beginning of the second half of the year, Zhongji Xuchuang has surged 156.40%, leading the gains, followed by Sunshine Power at 114.27%. Other significant performers include Lanke Technology and Yiwei Lithium Energy, both up over 60% [3]. Market Outlook - Looking ahead, the market is expected to maintain upward momentum as uncertainties gradually diminish. Liquidity is anticipated to remain supportive, with domestic interest rates low and overseas liquidity remaining loose, encouraging investment in Chinese equity assets [4][5]. - The current market environment is characterized by a shift in investment styles, with a focus on sectors that offer higher investment certainty, particularly in electronics, new energy, new consumption, and real estate [5].